{
    "clinical_study": {
        "@rank": "28238", 
        "arm_group": [
            {
                "arm_group_label": "Probiotics", 
                "description": "Capsule with 1 x 10**9 Lactobacillus rhamnosus GG and 1 x 10**8 Bifidobacterium BB12. Two capsules once a day. The capsules are opened and the content is dissolved in mother's milk or water if the baby is given any milk. In tube fed infants, two drops are given in the mouth and the rest in the nasogastric tube."
            }, 
            {
                "arm_group_label": "Control", 
                "description": "Probiotics never given"
            }
        ], 
        "brief_summary": {
            "textblock": "Probiotics is given routinely to infants admitted to the department of neonatology during\n      the first 3 days of life with gestational age less than 30 weeks since March 2010. The\n      incidence of necrotizing enterocolitis Bell stage II and III will be assessed blindly from\n      clinical records. It is hypothesised that the incidence of NEC will decrease. Infants\n      admitted from 1 March 2010 to 28 February 2013 will be compared to infants admitted 1 Dec\n      2007 to 30 Nov 2009 will be compared."
        }, 
        "brief_title": "Probiotics to Prevent NEC - a Historical Control Study", 
        "completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "condition": "Necrotizing Enterocolitis", 
        "condition_browse": {
            "mesh_term": [
                "Enterocolitis", 
                "Enterocolitis, Necrotizing"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Gestational age less than 30 weeks\n\n          -  Admission during the first 3 days of life"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "3 Days", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Newborn infants admitted for special or intensive care"
            }
        }, 
        "enrollment": {
            "#text": "714", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 17, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01670916", 
            "org_study_id": "RHNEO-NEC01"
        }, 
        "intervention": {
            "arm_group_label": "Probiotics", 
            "description": "Capsule with 1 x 10**9 Lactobacillus rhamnosus GG and 1 x 10**8 Bifidobacterium BB12. Two capsules once a day. The capsules are opened and the content is dissolved in mother's milk or water if the baby is given any milk. In tube fed infants, two drops are given in the mouth and the rest in the nasogastric tube.", 
            "intervention_name": "probiotics", 
            "intervention_type": "Dietary Supplement", 
            "other_name": [
                "Bifiform, Ferrosan A/S", 
                "Idoform, Ferronan A/S"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Necrotizing enterocolitis", 
            "Probiotics", 
            "Preterm", 
            "Infant"
        ], 
        "lastchanged_date": "September 30, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Copenhagen", 
                    "country": "Denmark", 
                    "zip": "2100"
                }, 
                "name": "Department of Neonatology, Rigshospitalet"
            }
        }, 
        "location_countries": {
            "country": "Denmark"
        }, 
        "number_of_groups": "2", 
        "official_title": "Probiotics to Prevent NEC Stage II+ in Very Preterm Infants - a Historical Control Study", 
        "other_outcome": {
            "description": "Growth of lactobacilli or bifidobacteria from a normally sterile fluid", 
            "measure": "Positive culture of probiotic bacteria", 
            "safety_issue": "Yes", 
            "time_frame": "Birth to discharge from Rigshospitalet"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Denmark: Danish Dataprotection Agency"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The clinical records of infants who had a discharge diagnosis of necrotizing enterocolitis are selected. Records of infants who had a prescription of metronidazole for a non-preventive purpose is added. The clinical records are abstracted. The abstracts and X-rays are presented to a review board that are blinded to the period of birth. The board classifies the cases as NEC-I, NEC-II, NEC-III, focal intestinal perforation, and OTHER.\nNEC-II/III is the primary outcome.", 
            "measure": "NEC", 
            "safety_issue": "No", 
            "time_frame": "From birth until discharge home"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01670916"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Rigshospitalet, Denmark", 
            "investigator_full_name": "Gorm Greisen", 
            "investigator_title": "professor, consultant neonatologist", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Death with a review board classification of NEC-II/III", 
                "measure": "Death with NEC", 
                "safety_issue": "No", 
                "time_frame": "Birth to discharge home"
            }, 
            {
                "measure": "Death", 
                "safety_issue": "Yes", 
                "time_frame": "Birth to discharge home"
            }
        ], 
        "source": "Rigshospitalet, Denmark", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Rigshospitalet, Denmark", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2010", 
        "study_design": "Observational Model: Case Control", 
        "study_type": "Observational", 
        "verification_date": "September 2013"
    }
}